# Implantica > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/implantica). ## Overview Implantica is a Liechtenstein-based medtech company focused on implantable medical technologies and related platform systems. Its first commercial product is RefluxStop®, an implant for treating acid reflux, alongside a pipeline that includes eHealth, wireless energising, and other implant-based solutions. ## Products & services • RefluxStop® implant for acid reflux treatment • eHealth platform technologies • Wireless energising / implant communication systems • UriRestore® urinary restoration technology • StomaRestore® stoma-related restoration technology - **RefluxStop®** (70%) — Implantable treatment for gastroesophageal reflux disease (acid reflux). - **Platform technologies** (10%) — Implant communication, wireless energising, and eHealth systems. - **Urinary restoration** (10%) — Implant-based solutions such as UriRestore® for urinary dysfunction. - **Stoma-related restoration** (10%) — Implant-based solutions such as StomaRestore® for stoma care and recovery. - RefluxStop® implant for acid reflux treatment - eHealth platform technologies - Wireless energising / implant communication systems - UriRestore® urinary restoration technology - StomaRestore® stoma-related restoration technology ## Customers Implantica sells primarily to hospitals, surgeons, and specialized medical centers that implant and follow up on its devices. Its commercial model depends on key opinion leaders, centers of excellence, and reimbursement bodies that influence adoption of new surgical technologies. Patients are the end beneficiaries, but purchasing and usage decisions are driven by clinicians and healthcare systems. - **Centers of excellence / hospitals** (primary) — Buy and use RefluxStop® for implantation in reflux patients and to build clinical experience. - **Key opinion leaders and specialist surgeons** (primary) — Adopt and recommend the technology, driving procedure volumes and clinical credibility. - **Payers and reimbursement bodies** (secondary) — Assess clinical evidence and cost-effectiveness before broad coverage decisions. - **Healthcare systems** (secondary) — Adopt technologies that can reduce repeat treatments and long-term care burden. - Hospitals and surgical centers performing RefluxStop® procedures - Key opinion leaders who influence clinical adoption - Specialist surgeons treating chronic acid reflux patients - Payers and reimbursement authorities evaluating cost-effectiveness - Healthcare systems seeking lower-repeat-treatment solutions ## Geography Implantica’s commercial footprint is concentrated in Europe, where it has built a base of hospitals and surgeons using RefluxStop®. The company highlights direct sales activity in Germany, Switzerland, Austria, the UK, Italy, Spain, Norway, and Sweden, while the United States is its main expansion market and Canada and Japan are longer-term targets. - **Europe** (100%) — Commercial base and current procedure activity are concentrated in Europe. - Core commercial activity is in selected European markets - Direct sales focus in Germany, Switzerland, Austria, and the UK - Also active in Italy, Spain, Norway, and Sweden - United States is the main next expansion market - Canada and Japan are planned follow-on markets ## Strategy Implantica’s strategy is to establish RefluxStop® as a standard treatment through clinical evidence, reimbursement progress, and surgeon adoption. It is also building a broader implant platform around eHealth, wireless communication, and additional products while preparing for U.S. commercialization and later international expansion. - **RefluxStop® commercialization and adoption** (short-term) — Procedure volume and surgeon acceptance are central to the company’s first revenue base. - **Reimbursement and market access** (short-term) — Coverage decisions determine whether hospitals can scale use of the implant. - **U.S. launch preparation** (medium-term) — The U.S. is the largest addressable market and a major growth opportunity. - **Platform and pipeline development** (medium-term) — Additional products broaden the company beyond a single lead implant. - Build clinical evidence to support adoption and reimbursement - Expand RefluxStop® commercialization in key European markets - Prepare for U.S. market entry after regulatory approval - Develop eHealth and wireless implant platform technologies - Protect core technology with patents and IP coverage ## Risks Implantica faces regulatory, clinical-adoption, and reimbursement risk because its business depends on new implantable technologies being accepted by surgeons, hospitals, and payers. As an early commercial medtech company, it also faces execution risk in scaling manufacturing, maintaining quality, and converting clinical evidence into durable market access. - **Regulatory approval and market access risk** [high] — Implantable devices require approvals and may face different rules across jurisdictions. - **Surgeon adoption risk** [high] — The company depends on clinicians learning, trusting, and using a new procedure. - **Reimbursement risk** [high] — Coverage and pricing decisions affect whether hospitals can scale adoption. - **Product quality and safety risk** [high] — Implantable devices can face recalls, adverse events, or regulatory action if issues arise. - **Execution and funding risk** [medium] — Commercialization, clinical studies, and product development require sustained capital and operational discipline. - Regulatory approval risk for new products and U.S. launch - Surgeon adoption depends on education and clinical confidence - Reimbursement delays can slow hospital uptake - Quality or safety issues could trigger recalls or restrictions - Early-stage commercialization increases execution and funding risk ## Accounting Implantica’s reporting is shaped by development-stage accounting, including capitalization and amortization of development costs and annual impairment testing of intangible assets not yet in use. Revenue is still limited and likely sensitive to timing of procedures, while foreign exchange movements and clinical/commercial rollout costs can create volatility in reported results. - **Capitalized development costs and amortization** — Affects operating profit and asset carrying values - **Impairment testing of intangible assets** — Can create large non-cash write-downs - **Foreign currency translation** — Can move financial income/expense materially - **Going concern and estimate judgments** — Affects valuation of development assets and disclosures - Capitalized development costs are amortized after market launch - Intangible assets in development are tested for impairment annually - Revenue timing may vary with procedure volumes and market rollout - Foreign currency gains and losses can affect reported earnings - Going-concern and estimate judgments matter for development assets --- *Last updated: 2026-08-11T04:04:53.374957+00:00*